Skip to main content
Premium Trial:

Request an Annual Quote

Epic Sciences Receives CAP Accreditation

NEW YORK (GenomeWeb) – Epic Sciences announced today that its San Diego laboratory has received accreditation from the College of American Pathologists.

Epic markets a platform it calls "no cell left behind," which isolates circulating tumor cells in an unbiased manner, allowing downstream analyses of single CTCs using genomic, proteomic, and morphologic approaches.

CAP accreditation is designed to ensure a high standard of care for the laboratory testing of patient samples. As part of the process, CAP inspectors examine a lab's records and quality control of procedures, as well staff qualifications, equipment, facilities, safety records, and overall management.

Epic Sciences said it has analyzed more than 10,000 blood samples from cancer patients and that its technology is being used in more than 58 active clinical trials.

The company received CLIA certification for its lab in early 2015.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.